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ABST RACT
Introduction. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired
non-malignant hematological disorder which affects the pluripotent
hematopoietic stem cell. The cause of PNH development is the occurrence of
somatic mutations in the phosphatidylinositol glycan-A gene which encodes a
protein necessary for the biosynthesis of glycosylphosphatidylinositol
anchors. The diagnosis of PNH requires the presence of signs of intravascular
hemolysis, thrombosis, and (or) bone marrow failure. Case Report. We report
the case of a 42-year-old female, diagnosed with PNH at the age of 27, whose
evolution was initially characterized predominantly by hemolytic attacks and
whose disease pattern evolved towards thromboembolic episodes with the
advancement of age. Conclusions. Establishing the diagnosis of PNH is a
difficult task and its management requires teamwork. During the evolution of
the disease, a PNH patient can acquire supplementary risk factors for
thrombosis, in addition to the pro-coagulant potential of the disease itself. We
reported this case to remind physicians that establishing the diagnosis of PNH
is troublesome, and thus it is questionable whether PNH is a rare disease or
just underdiagnosed. In this context, in the clinical practice of hematologists
and other physicians as well, PNH remains a veritable Pandora's box.
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Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is an
acquired non-malignant hematological disorder which
affects the pluripotent hematopoietic stem cell. The cause
of PNH development is the occurrence of somatic
mutations in the phosphatidylinositol glycan-A (PIGA)
gene located on the X chromosome (Xp22.1) which
encodes a protein necessary for the biosynthesis of
glycosylphosphatidylinositol (GPI) anchors [1-4].
Consequently, in PNH there is a deficiency in proteins that
employ GPI anchors to bind to the surface of blood cells,
such as decay-accelerating factor (DAF or CD55) and
membrane inhibitor of reactive lysis (MIRL or CD59).
These molecules are involved in the inhibition of the
membrane attack complex (MAC), regulating the action of
the complement system activated via the alternative
pathway (Figure 1) [1, 2]. Although all cell lines derived
from the affected stem cell are deficient in GPI-anchored
proteins, erythrocytes are more likely to be destroyed by
complement-mediated lysis since they lack a nucleus [2].

PNH is characterized by phenotypic mosaicism [4]:
• the sensitivity of type I clones to complementmediated lysis is normal. The expression of MIRL
(CD59) and DAF (CD55) on the surface of
erythrocytes is normal.
• the sensitivity of type II clones to complementmediated lysis is 2-4 times higher than normal. These
cells have a partial deficiency in MIRL and DAF. The
clinical course of PNH patients whose erythrocytes’
phenotype corresponds to type II clones is benign,
suffering from hemolytic crises only when
supervening events (infections, trauma etc.) lead to
the brisk activation of the complement system.
• the sensitivity of type III clones to complementmediated lysis is 15-25 times higher than normal.
These cells are totally deficient in MIRL and DAF
and, thus, a higher representation of this clone will
lead to a severe clinical PNH course.
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Although PNH is regarded as a rare disease in clinical
practice, with an estimated incidence of 1-1.5/1.000.000,
this hematological disease might be underdiagnosed, mainly
due to its myriad of presenting conditions: anemia and
related-symptoms, thrombosis, smooth muscle dystonia,

fatigue, hemoglobinuria due to intravascular hemolysis,
renal impairment, or pulmonary hypertension [2]. Herein,
we present the case of a female patient with long-lasting
PNH, with special emphasis on the onset, evolution, and
management of this great mimicking disease.

Figure 1. Activation of the complement system via the alternative pathway. Role of DAF, MIRL and Eculizumab.

Case Presentation
We report the case of a 42-year-old female, initially
diagnosed at 15 years of age in a pediatric unit with Evans
syndrome, based on the presence of hemolytic anemia
(Coombs test slightly positive) and thrombocytopenia. The
patient was treated with prednisone and cyclophosphamide
pulse-therapy without any response and was subjected to
splenectomy 12 months after the first hospitalization. At
the age of 18, the patient was admitted to an Internal
Medicine unit with abdominal discomfort in the upper right
quadrant and jaundice. Abdominal ultrasound revealed the
partial thrombosis of a branch of the portal vein and the
presence of an accessory spleen. In this context,
anticoagulation therapy with LMWH and thereafter
acenocoumarol was prescribed.
The patient was lost for follow-up for nearly 7 years
and was admitted at the age of 27 to the Hematology Clinic,
Fundeni Clinical Institute, Bucharest, Romania, with fever,
jaundice, severe macrocytic anemia with a pattern of
hemolysis, slight leukopenia, low haptoglobin, dark urine
(hemoglobinuria), elevated LDH, low C3 values, negative
Coombs test, low ferritin and leukocyte alkaline
phosphatase levels, negative anti-DNAds, anti-Ro/SSA
and anti-LA/SSB antibodies, positive Ham (Figure 2) and
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sucrose tests, and a positive test for hemosiderinuria (the
main blood tests results are reported in Table 1). The final
diagnosis of PNH was established before any blood
transfusions,
based
on
peripheral
blood
immunophenotyping by flow-cytometry. The flowcytometric analysis showed a dominant PNH clone within
the granulocytes (98% type II), monocytes (98% type II)
and a minor PNH clone in the red blood cells (7.9% type II
and 0.8% type III, decreased expression of CD59).
Concomitantly, the patient was diagnosed with hepatitis C
and blood tests indicated signs of autoimmunity (positive
rheumatoid factor and positive antinuclear antibodies).

Figure 2. Representation of the Ham test in the
workup of PNH.
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Table 1. Laboratory tests results in our patient at the
time of the PNH diagnosis.
Laboratory
parameters

PNH case

Reference
values

Hemoglobin

5 g/dL

11.2-17.5 g/dL

Mean Corpuscular
Volume

114.6 fL

80.0-100.0 fL

Reticulocyte count

22%

1-2%

Leukocytes

3800
leukocytes/mmc

3980-10000
leukocytes/mmc

Haptoglobin

0.03 g/L

0.3-2 g/L

Ferritin

14 ng/mL

20-300 ng/mL

Leukocyte alkaline
phosphatase score

0

10-100

Lactate
dehydrogenase

4007 mmol/L

135-225
mmol/L

C3

86 mg/dL

90-180 mg/dL

Until 2019, the patient was treated conservatively
(blood transfusions and anticoagulants), since eculizumab
(recombinant humanized monoclonal antibody targeted
against the complement protein C5) could not be
prescribed to manage any hemolytic crisis as the drug was
not available in Romania. The evolution of the patient was
characterized by hemolytic crises triggered by common
infections and (or) menses. In June 2019, the patient
presented to the Neurology Clinic of our hospital with
dysarthria, paresthesia, and loss of function of the upper
left limb as signs of a stroke. She had also developed
obesity and hypertension.
Computed tomography revealed:
• spontaneous cortico-subcortical hypodensity with loss
of grey-white matter differentiation located in the right
frontal area (compatible with a subacute ischemic
stroke).
• small spontaneous hypodense lesion similar in density
to the cerebrospinal fluid depicted as a craniocaudal
band in the frontal white matter on the right side
(possible sequelae lesion).
• minimal calcified atheromata of the parasellar segment
of the internal carotid artery and left vertebral artery.
The patient received LMWH, mannitol, and
cerebrolysin, followed by co-administration of
acenocoumarol and LMWH, and was ultimately
discharged with the recommendation to continue
acenocoumarol treatment indefinitely. The patient had
admitted the administration of herbal supplements for
weight loss and she was advised not to consume such
products due to a possible interaction with acenocoumarol.

Also, Doppler echocardiography revealed the presence of
an atrial septal defect (possible ostium secundum) and
distal occlusion of the internal carotid artery.
In July 2019, the patient was hospitalized in our clinic
for abdominal discomfort and nausea, with normal
hemoglobin, no clinical or biological signs of a hemolytic
attack, elevated liver enzymes and elevated amylase and
lipase. Based on the abdominal ultrasound, the diagnosis of
chronic cholecystitis with possible involvement of the
pancreas was established. The patient was treated with
antibiotics, antispasmodics, and antisecretory medication
and was discharged with the recommendation of
laparoscopic cholecystectomy if the symptoms persisted.
In January 2020, due to the development of pericholecystic
adhesions, open cholecystectomy was performed and the
patient was discharged seven days after the surgical
procedure.
Soon after the intervention, the patient was admitted to
the Neurology Clinic of our hospital with left central facial
paresis, left hemiplegia (0/5 on the Medical Research
Council scale), and left hemihypesthesia. The examination
by carotid ultrasound imaging underlined the occlusion of
the internal right carotid artery. Also, echocardiographic
examination revealed the presence of a patent foramen
ovale with a right-to-left shunt. Blood tests revealed the
presence of lupus anticoagulant and a positive cryoglobulin
test (++). Screening for thrombophilia was negative.
Computed tomography was performed, showing an area of
early sub(acute) ischemia located in the frontoparietal
region, indicative of a re-infarction in the right frontal area,
and no signs of hemorrhagic transformation. Magnetic
resonance imaging also confirmed the presence of bilateral
supratentorial acute ischemic stroke, especially in the right
fronto-parietal region, and multiple acute lacunar lesions
which suggested a possible embolic etiology.

Discussions
We have presented the case of a patient with longlasting PNH. Although the evolution of PNH in her case
was typical, the definitive diagnosis was established only
around the age of 27. The onset of the clinical signs was
precocious, during adolescence, but was misinterpreted as
Evans syndrome, i.e., autoimmune hemolytic anemia and
autoimmune thrombocytopenia, frequently associated with
systemic lupus erythematosus [5]. Thus, the definitive
diagnosis of PNH was delayed. However, the development
of thrombotic complications in unusual sites, namely
splanchnic thrombosis, should have oriented the clinical
reasoning towards the correct diagnosis. According to Fan
et al. (2019), PNH is a risk factor for noncirrhotic
nonmalignant portal vein thrombosis and Budd-Chiari
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syndrome. However, myeloproliferative neoplasms and
mutations in thrombophilia-related genes (factor V Leiden
G1691A, prothrombin G20210A) comprise the most
frequent genetic association with the two aforementioned
conditions [6]. Interestingly, splanchnic thrombosis at a
young age is not uncommon in PNH, with Ain et al. (2018)
reporting the occurrence of splanchnic thrombosis in a
PNH female patient of just 14 years of age, who presented
to the hospital with abdominal pain, palpitations and
dyspnea. In her case, blood tests revealed the presence of
hemolytic anemia and a negative Coombs test, and the final
diagnosis of PNH was confirmed by flow-cytometry (the
erythrocytes had lost the expression of CD59) [7]. The
diagnosis of PNH requires the presence of signs of
intravascular hemolysis, thrombosis, and (or) bone marrow
failure. In our case report, the definitive diagnosis was
established with great difficulty because the presentation
of these signs was sequential, spanning a time frame of
approximately 12 years.
Interestingly, in our case, the pattern of disease changed
over time. Up to the age of 42, the patient experienced
numerous hemolytic attacks triggered by supervening
events (infections, menses etc.) and only one thrombotic
episode, namely the visceral splanchnic thrombosis
involving the portal vein. Thereafter, the PNH pattern
changed from predominantly hemolytic to predominantly
thrombotic (with recurrent ischemic stroke involving the
frontal region of the cortex), probably in direct relationship
with the presence of the patent foramen ovale, occlusion of
the internal carotid artery, additional cardiovascular risk
factors (e.g. hypertension, obesity), the positive lupus
anticoagulant and cryoglobulin test, as well as to the fact
that the patient had previously undergone splenectomy.
Patent foramen ovale is a possible cause of cryptogenic
stroke in young adults, and recurrent ischemic stroke due
to patent foramen ovale has already been reported in PNH
patients [8-10]. Moreover, patients who underwent
splenectomy seem to have a higher incidence of
thromboembolic events, with portal-splenic mesenteric
vein thrombosis being the most common finding [11]. Our
patient associated additional risk factors for thrombosis
(obesity,
hypertension,
lupus
anticoagulant,
cryoglobulins), although the screening for thrombophilia
yielded negative results. Thus, as a take-home message,
close monitoring of the patient diagnosed with PNH is of
utmost importance, since ageing also leads to the
acquisition of new disorders. Also, PNH patients who
experience
thrombosis
should
be
prescribed
anticoagulation therapy indefinitely [12-14]. The possible
pathophysiological links explaining the evolution of PNH
in this case report are depicted in Figure 3.
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Figure 3. Possible pathophysiological links explaining
the evolution of PNH in our patient.
The patient would have been an ideal candidate for
eculizumab, a recombinant humanized monoclonal
antibody targeted against the complement protein C5, for
multiple reasons: young age, intermediary-high risk,
dominant major PNH major clone (type II PNH
clone >80% within the granulocytes), frequent hemolytic
attacks, and thrombotic events. However, the drug was
unavailable in Romania at the time.

Highlights
✓ Paroxysmal nocturnal hemoglobinuria (PNH) is an
acquired non-malignant hematological disorder which
affects the pluripotent hematopoietic stem cell.
✓ PNH is characterized by intravascular hemolysis,
thrombosis, and (or) bone marrow failure.
✓ Although the clinical picture in PNH is dominated by
the presence of hemolytic attacks, sometimes the
pattern of the disease can change towards the
predominance of thromboembolic episodes.

Conclusions
Establishing the diagnosis of PNH is a difficult task and
its management requires teamwork. During the evolution
of the disease, a PNH patient can acquire supplementary
risk factors for thrombosis (obesity, hypertension,
hypercholesterolemia), in addition to the pro-coagulant
potential of the disease itself. Thus, the patient should be
closely monitored. We reported this case to remind
physicians that establishing the diagnosis of PNH is
troublesome, and thus it is questionable whether PNH is a
rare disease or just underdiagnosed. In this context, in the
clinical practice of hematologists as well as other
physicians, PNH remains a veritable Pandora's box.
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antibodies,
anti-double-stranded
deoxyribonucleic acid antibodies.
Anti-Ro/SSA antibodies, anti-Sjögren’s-syndromerelated antigen A antibodies.
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Anti-LA/SSB antibodies, anti-Sjögren’s-syndromerelated antigen B antibodies.
CD, cluster of differentiation.
DAF, decay-accelerating factor.
GPI, glycosylphosphatidylinositol.
LMWH, low molecular weight heparin.
MAC, membrane attack complex.
MIRL, membrane inhibitor of reactive lysis.
PIGA, phosphatidylinositol glycan-A.
PNH, paroxysmal nocturnal hemoglobinuria.
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